Skip to search formSkip to main contentSkip to account menu

GW 572016

Known as: GW-572016, GW572016 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

lapatiniblapatinib ditosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Highly Cited
2008
Highly Cited
2008
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… 
Highly Cited
2006
Highly Cited
2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… 
Review
2006
Review
2006
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
Objective: To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of lapatinib… 
Highly Cited
2005
Highly Cited
2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients…
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with… 
Review
2005
Review
2005
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy… 
Highly Cited
2005
Highly Cited
2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of… 
Highly Cited
2005
Highly Cited
2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
PURPOSE This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients… 
Highly Cited
2004
Highly Cited
2004
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… 
Highly Cited
2002
Highly Cited
2002
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)